Ascorbic acid overdose
Pro Research Analysisby 
Searched over 200M research papers
Ascorbic Acid Overdose: Risks and Pharmacokinetics
Introduction to Ascorbic Acid Overdose
Ascorbic acid, commonly known as vitamin C, is widely used as a dietary supplement. While it is essential for various bodily functions, excessive intake can lead to adverse effects. This article explores the risks associated with ascorbic acid overdose, particularly focusing on its impact on kidney health and the pharmacokinetic limitations of high doses.
Risk of Calcium Oxalate Nephrolithiasis
Increased Urinary Oxalate Excretion
One of the primary concerns with high doses of ascorbic acid is the increased risk of calcium oxalate nephrolithiasis, commonly known as kidney stones. Research has shown that doses of 500 mg or more of ascorbic acid significantly increase urinary oxalate levels. This increase is equivalent to 1.2 to 1.8% of the millimoles of ascorbate administered, translating to an additional 6 to 13 mg of urinary oxalate per day per 1,000 mg of ascorbic acid supplement . This elevated oxalate excretion heightens the risk of forming calcium oxalate stones in the kidneys.
Pharmacokinetic Limitations of Megadoses
Saturable Absorption and Renal Clearance
The pharmacokinetics of ascorbic acid reveal that the body has a limited capacity to absorb and utilize high doses. When the daily oral dose of ascorbic acid is increased from 200 to 2,500 mg, the plasma concentration only rises modestly from approximately 12 to 15 mg/L. This phenomenon is due to the saturable nature of gastrointestinal absorption and renal clearance. As plasma concentrations increase, renal clearance of ascorbic acid also rises sharply because of saturable tubular reabsorption . Consequently, there is a ceiling effect, beyond which higher doses do not result in proportionally higher plasma concentrations, negating the pharmacokinetic justification for megadoses.
Clinical Implications in Critically Ill Patients
Mortality and Support Duration
In critically ill patients, the administration of ascorbic acid has shown mixed results. A meta-analysis of various trials indicated that intravenous doses of 3-10 g/day reduced mortality rates significantly (OR 0.25; 95% CI 0.14-0.46; p < 0.001). However, doses below 3 g/day or above 10 g/day did not show a significant impact on mortality (OR 1.44; 95% CI 0.79-2.61; p = 0.234 and OR 1.12; 95% CI 0.62-2.03; p = 0.700, respectively) . Additionally, ascorbic acid was associated with a decreased duration of vasopressor support and mechanical ventilation, although it did not affect fluid requirements or urine output during the first 24 hours of admission.
Conclusion
While ascorbic acid is beneficial in appropriate doses, excessive intake poses significant risks, particularly concerning kidney health and the formation of calcium oxalate stones. The pharmacokinetic properties of ascorbic acid further limit the effectiveness of megadoses, as the body cannot efficiently utilize such high amounts. In clinical settings, moderate doses of intravenous ascorbic acid may offer benefits for critically ill patients, but further research is needed to fully understand its efficacy and safety.
Sources and full results
Most relevant research papers on this topic